Pfizer Discontinues SUN 1094 Trial Of Sunitinib Plus Paclitaxel In Advanced Breast Ca
Pfizer Inc announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer.